Seres Therapeutics, Inc. (MCRB) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Seres Therapeutics, Inc. is a pioneering microbiome therapeutics firm dedicated to engineering bacterial consortia that modulate host cells and tissues to combat various diseases. Their flagship therapeutic, SER-109, an oral microbiome treatment, has successfully concluded Phase III clinical trials for the management of Clostridioides difficile infection (CDI).
Analysis Summary
Seres Therapeutics, Inc. reported revenue of $789000 in the most recent fiscal year, growing at a 5-year CAGR of -52.7%.
Trailing-twelve-month margins: gross margin 82.6%, operating margin -44.6%, net margin -11.9%.
At the current price of $4.21, MCRB has negative trailing earnings (P/E not meaningful) and an ROE of -60.32%. Market capitalisation stands at $41M.
Balance sheet quality for MCRB: current ratio of 2.6, net debt of $37.2M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Cash flow quality is below average: free cash flow of $865000 represents 15% conversion of reported net income. High conversion (above 90%) suggests earnings translate cleanly into cash; lower conversion may indicate working capital tightness or accounting timing differences.
Price
| Price | $4.21 |
| Market Cap | $41M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.32 |
| EV / EBITDA | -2.17 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -60.32% |
| Return on Invested Capital | -89.99% |
| Return on Assets | -22.11% |
| Gross Margin | 82.58% |
| Operating Margin | -4462.77% |
| Net Margin | -1192.94% |
Financial Health
| Debt / Equity | 1.64 |
| Current Ratio | 2.11 |
| Piotroski F-Score | 5 |
| Altman Z-Score | -10.99 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| MCRB | Seres Therapeutics, Inc. | $41M | 1.32 | -60.3% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price Performance
| 1 month | -3.00% |
| 3 months | -36.31% |
| Year-to-date | -71.71% |
| 1 year | -76.09% |
| 3 years | -92.35% |
| 5 years | -97.04% |
52-Week Range
| 52-week High | $29.98 |
| 52-week Low | $4.18 |
| Avg Volume (90d) | 77K |
Related companies: ABOS · ACTU · APLT · CGTX · HURA · INO · IRD
Explore sector: Healthcare · Biotechnology
More sections of MCRB: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks